UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 64

Sortiert nach

Multicenter randomized‐controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after ileo‐caecal resection

Inflammatory bowel diseases, 2007-02, Vol.13 (2), p.135-142

2007

Link zum Volltext

Verfügbarkeit prüfen

S734 IBD Patients’ Treatment Preferences Are Heterogeneous, but Largely Affected by the Avoidance of Abdominal Pain and Side Effects (P-POWER IBD Study)

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S337-S337

2021

Link zum Volltext

Verfügbarkeit prüfen

S0643 Composite and Individual Measures of Efficacy and Safety of Upadacitinib Treatment for Crohn's Disease: 12-Month Results From the Ongoing Phase 2 CELEST Open-Label Extension Study

The American journal of gastroenterology, 2020-10, Vol.115 (1), p.S322-S323

2020

Link zum Volltext

Verfügbarkeit prüfen

S943 Analysis of International Spontaneous Reporting System Databases for Safety of Corticosteroids in Inflammatory Bowel Disease: The Determinants, Incidence and Consequences of Corticosteroid Excess (DICE)-Impact Study

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S448-S449

2021

Link zum Volltext

Verfügbarkeit prüfen

The Real World Global Use of Patient-Reported Outcomes (PROs) for the Care of Patients With IBD

The American journal of gastroenterology, 2022, Vol.117 (10 Suppl.), p.S704

2022

Link zum Volltext

Verfügbarkeit prüfen

S713 Induction and Maintenance Treatment with Risankizumab Leads to Symptomatic Relief in Patients With Moderate to Severe Crohn’s Disease

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e496-e497

2022

Link zum Volltext

Verfügbarkeit prüfen

S822 Fatigue Improvement Correlates With Reductions in Work Productivity Impairment and Related Indirect Cost in Patients With Crohn’s Disease: Post Hoc Analysis of Phase 3 Rizankizumab Induction Trials

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e591-e592

2022

Link zum Volltext

Verfügbarkeit prüfen

S4 Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study

The American journal of gastroenterology, 2023-12, Vol.118 (12S), p.S2-S2

2023

Link zum Volltext

Verfügbarkeit prüfen

S845 Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study

The American journal of gastroenterology, 2023-10, Vol.118 (10S), p.S624-S625

2023

Link zum Volltext

Verfügbarkeit prüfen

S737 Effect of Risankizumab on Patient-Reported Outcomes in Patients With Crohn’s Disease With Inadequate Response or Intolerance to Conventional And/or Biologic Treatments: Results From Phase 3 MOTIVATE and ADVANCE Trials

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S338-S338

2021

Link zum Volltext

Verfügbarkeit prüfen

An Analysis of Latest Data on Sequential Use of Biologic Therapies in Patients with Inflammatory Bowel Disorder: A Systematic Literature Review: 715

The American journal of gastroenterology, 2018-10, Vol.113 (Supplement), p.S401-S402

2018

Link zum Volltext

Verfügbarkeit prüfen

S37 Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients With Moderately to Severely Active Crohn’s Disease: U-ENDURE Phase 3 Results

The American journal of gastroenterology, 2022-12, Vol.117 (12S), p.S10-S10

2022

Link zum Volltext

Verfügbarkeit prüfen

S972 The Real World Global Use of Patient-Reported Outcomes (PROs) for the Care of Patients With IBD

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e704-e705

2022

Link zum Volltext

Verfügbarkeit prüfen

806 Long-Term Safety and Efficacy of Risankizumab Treatment in Patients With Crohn’s Disease: 3-Year Interim Results From the Ongoing Phase 2 Open-Label Extension Study

The American journal of gastroenterology, 2019-10, Vol.114 (1), p.S466-S466

2019

Link zum Volltext

Verfügbarkeit prüfen

S0815 Effect of Mirikizumab on Inflammatory Biomarkers in a Phase 2 Study of Patients With Crohn’s Disease

The American journal of gastroenterology, 2020-10, Vol.115 (1), p.S418-S419

2020

Link zum Volltext

Verfügbarkeit prüfen

S736 Efficacy and Safety of Upadacitinib Induction Therapy in Patients With Moderately to Severely Active Crohn’s Disease: Results From a Randomized Phase 3 U-EXCEL Study

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e518-e518

2022

Link zum Volltext

Verfügbarkeit prüfen

S789 Effect of Mirikizumab on Inflammatory Biomarkers in a Phase 2 Study of Patients With Crohn’s Disease

The American journal of gastroenterology, 2021-10, Vol.116 (1), p.S367-S367

2021

Link zum Volltext

Verfügbarkeit prüfen

672 Defining Meaningful Attributes for the Treatment of IBD From Patients' Perspective

The American journal of gastroenterology, 2019-10, Vol.114 (1), p.S395-S395

2019

Link zum Volltext

Verfügbarkeit prüfen

834 Early Symptom Improvement With Risankizumab Treatment in Patients With Moderately to Severely Active Crohn’s Disease: Analysis From a Phase 2 Study

The American journal of gastroenterology, 2019-10, Vol.114 (1), p.S482-S482

2019

Link zum Volltext

Verfügbarkeit prüfen

S0881 Therapeutic Drug Monitoring Dosing Regimen With Adalimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the SERENE-UC Maintenance Study

The American journal of gastroenterology, 2020-10, Vol.115 (1), p.S454-S454

2020

Link zum Volltext

Verfügbarkeit prüfen

S0648 Clinically Adjusted vs Therapeutic Drug Monitoring Dosing Regimens With Adalimumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the SERENE-CD Maintenance Study

The American journal of gastroenterology, 2020-10, Vol.115 (1), p.S325-S326

2020

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic Targeting of Specific Populations (Pharmacogenetics)

Inflammatory bowel diseases, 2006-04, Vol.12, p.S15

Louis, Edouard

2006

Link zum Volltext

Verfügbarkeit prüfen

Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C‐reactive protein serum level

Inflammatory bowel diseases, 2007-09, Vol.13 (9), p.1100-1105

2007

Link zum Volltext

Verfügbarkeit prüfen

P037 LONG-TERM SAFETY, EFFICACY AND PHARMACOKINETICS OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) MONOCLONAL ANTIBODY SHP647 IN CROHN’S DISEASE: THE OPERA II STUDY

Inflammatory bowel diseases, 2019-02, Vol.25 (Supplement_1), p.S18-S19

2019

Link zum Volltext

Verfügbarkeit prüfen

Sustained Resolution of Extraintestinal Manifestations in Patients with Crohnʼs Disease Receiving Adalimumab: 670

The American journal of gastroenterology, 2016-10, Vol.111, p.S305

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 64

Suche als RSS-Feed

Aktive Filter

ThemaCenozoic

ThemaLife Sciences & Biomedicine

KollektionWiley Online Library Journals Frontfile Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(61)
Mit Volltextzugriff
(24)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Wiley Journals
(64)
Journals@OVID
(55)
IngentaConnect Journals
(43)
IngentaConnect
(43)
Nature Journals Online
(40)
NUS Single-Journal Subscriptions
(40)
Wiley Online Library Full Collection 2018
(13)
Oxford University Press Journals Current
(10)
Oxford Journals 2020 Medicine
(9)
EZB Free E-Journals
(6)
MEDLINE
(5)
JSTOR
(2)

7 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Multicenter randomized‐controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after ileo‐caecal resection

S734 IBD Patients’ Treatment Preferences Are Heterogeneous, but Largely Affected by the Avoidance of Abdominal Pain and Side Effects (P-POWER IBD Study)

S0643 Composite and Individual Measures of Efficacy and Safety of Upadacitinib Treatment for Crohn's Disease: 12-Month Results From the Ongoing Phase 2 CELEST Open-Label Extension Study

S943 Analysis of International Spontaneous Reporting System Databases for Safety of Corticosteroids in Inflammatory Bowel Disease: The Determinants, Incidence and Consequences of Corticosteroid Excess (DICE)-Impact Study

The Real World Global Use of Patient-Reported Outcomes (PROs) for the Care of Patients With IBD

S713 Induction and Maintenance Treatment with Risankizumab Leads to Symptomatic Relief in Patients With Moderate to Severe Crohn’s Disease

S822 Fatigue Improvement Correlates With Reductions in Work Productivity Impairment and Related Indirect Cost in Patients With Crohn’s Disease: Post Hoc Analysis of Phase 3 Rizankizumab Induction Trials

S4 Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study

S845 Risankizumab Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomized Phase 3 INSPIRE Study

S737 Effect of Risankizumab on Patient-Reported Outcomes in Patients With Crohn’s Disease With Inadequate Response or Intolerance to Conventional And/or Biologic Treatments: Results From Phase 3 MOTIVATE and ADVANCE Trials

An Analysis of Latest Data on Sequential Use of Biologic Therapies in Patients with Inflammatory Bowel Disorder: A Systematic Literature Review: 715

S37 Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients With Moderately to Severely Active Crohn’s Disease: U-ENDURE Phase 3 Results

S972 The Real World Global Use of Patient-Reported Outcomes (PROs) for the Care of Patients With IBD

806 Long-Term Safety and Efficacy of Risankizumab Treatment in Patients With Crohn’s Disease: 3-Year Interim Results From the Ongoing Phase 2 Open-Label Extension Study

S0815 Effect of Mirikizumab on Inflammatory Biomarkers in a Phase 2 Study of Patients With Crohn’s Disease

S736 Efficacy and Safety of Upadacitinib Induction Therapy in Patients With Moderately to Severely Active Crohn’s Disease: Results From a Randomized Phase 3 U-EXCEL Study

S789 Effect of Mirikizumab on Inflammatory Biomarkers in a Phase 2 Study of Patients With Crohn’s Disease

672 Defining Meaningful Attributes for the Treatment of IBD From Patients' Perspective

834 Early Symptom Improvement With Risankizumab Treatment in Patients With Moderately to Severely Active Crohn’s Disease: Analysis From a Phase 2 Study

S0881 Therapeutic Drug Monitoring Dosing Regimen With Adalimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the SERENE-UC Maintenance Study

S0648 Clinically Adjusted vs Therapeutic Drug Monitoring Dosing Regimens With Adalimumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the SERENE-CD Maintenance Study

Therapeutic Targeting of Specific Populations (Pharmacogenetics)

Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C‐reactive protein serum level

P037 LONG-TERM SAFETY, EFFICACY AND PHARMACOKINETICS OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) MONOCLONAL ANTIBODY SHP647 IN CROHN’S DISEASE: THE OPERA II STUDY

Sustained Resolution of Extraintestinal Manifestations in Patients with Crohnʼs Disease Receiving Adalimumab: 670

Aktive Filter

Suchergebnisse filtern